title: [Neuroleptic malignant syndrome].
abstract: The neuroleptic malignant syndrome (NMS) is presumably caused by neuroleptic blockade of dopamine receptors, mainly in the basal ganglia and hypothalamus. Symptoms include hyperthermia, muscular rigidity, and elevated serum creatine phosphokinase level, also autonomic dysfunction and, facultatively, impairment of consciousness. Clinical features, differential diagnosis and pathogenesis are discussed, as well as therapy with standard drugs as well as intravenous lisuride.
authors.affiliation: Neurologische Klinik, Ruhr-Universität, Bochum, Bundesrepublik Deutschland.
authors.forename: B
authors.initials: B
authors.lastname: Sczesni
authors.forename: J
authors.initials: J
authors.lastname: Schröder
authors.forename: H
authors.initials: H
authors.lastname: Becker
authors.forename: H
authors.initials: H
authors.lastname: Przuntek
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects*; D001479:Basal Ganglia / Q000187:drug effects; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects; D008090:Lisuride / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy / Q000209:etiology*; D011954:Receptors, Dopamine / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D008090:Lisuride
vernacular_title: Das neuroleptische maligne Syndrom.